Recent Biotechnology Acquisitions in Colorado
Acquisition Volume in Biotechnology in Colorado by Year
Last 5 years
-
August 16, 2024
- Buyer
- Energy Fuels Inc.
- Target
- RadTran LLC
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Buyout
Energy Fuels Inc. acquired RadTran LLC, a private specialist in radioisotope separation, to accelerate development and production of medical isotopes (notably Ra-226 and Ra-228) used in targeted alpha therapies for cancer. The deal (closed August 16, 2024) paid $1.5M cash, $1.5M in shares, a 2% royalty on future radium revenues and up to $14M in additional cash/shares tied to milestones; RadTran's CEO Saleem Drera joins Energy Fuels to lead radioisotope efforts.
-
- Buyer
- BroadOak Capital Partners
- Target
- KromaTiD, Inc.
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Growth capital
BroadOak Capital Partners provided $2.0 million of growth capital to KromaTiD to accelerate commercialization, support product development (including dGH In-Site and dGH SCREEN) and expand capacity to meet rising demand. KromaTiD, a Longmont, Colorado-based provider of single-cell genomic structural analysis for gene editing and gene therapy applications, will use the funding to grow its services and product offerings to biopharma and research customers.
-
- Buyer
- CanBiocin Inc.
- Target
- Pure Cultures Inc. (assets)
- Seller
- Pure Cultures Inc., Steve Kazemi
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Buyout
Edmonton-based CanBiocin Inc. acquired all assets of Denver-based Pure Cultures Inc., effective April 30, 2020, including species-specific probiotics, a U.S. patent and product brands Flock Vitality and Pig Vitality. The acquisition establishes CanBiocin operations in the United States and brings Pure Cultures founder Steve Kazemi into CanBiocin as Chief Commercialization Officer; deal terms were not disclosed.
-
April 6, 2020
- Buyer
- NewLeaf Brands Inc.
- Target
- Mydecine Group
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Buyout
NewLeaf Brands Inc. signed an LOI and subsequently a definitive agreement in April 2020 to acquire Mydecine Group, a Colorado-headquartered company focused on medicinal and infused mushroom cultivation, processing, product development and R&D. The deal contemplated the purchase of 100% of Mydecine for USD $850,000 payable in NewLeaf common shares; NewLeaf later operated the business as a wholly-owned subsidiary and rebranded to Mydecine Innovations Group.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.